A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

NCT05236257 · clinicaltrials.gov ↗

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
Infantile Fibrosarcoma

Interventions

DRUG: Larotrectinib (Vitrakvi, BAY2757556)
DRUG: Standard of Care

Sponsor

Bayer